Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Nov 26, 2021 6:14pm
167 Views
Post# 34171049

RE:RE:2021 ADRIQ Innovation Award

RE:RE:2021 ADRIQ Innovation Award The award is deserved for their potentially great scientific achievement with TH-1902 and the Sort1+ platform, but it would be nice if these scientific achievements would translate into better market performance more quickly. TH ha long been very good on the scinetific end of their operations but weak in marketing and public/investor relations. Like really, really weak. Unacceptably weak. So, I hope they enjoy their award but simultaneously understand that investors like they need to significantly up their game on the other aspects of the business. If you get fast track status, attract cancer experts like Soleus to invest in TH, recruit the recently retired CMO  of Pfizer as a Scientific consultant (and already having one of the top endocronoligists in the world as another scientific consultant) but can't get investors to properly understand the significance of these developments during a period of time when it should be easier than ever to do so, you really need to make big changes in how you approach the problem. In TH's case, its long, long term issues with investor engagement somehow has only gone from bad to worse in the last few years. It is so bad now that it should not be too hard to start seeing a positive change in trend with any sensible and concerted effort to rectify the problem. 

Bucknelly21 wrote: Another Qubec based non event lol 


<< Previous
Bullboard Posts
Next >>